Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings

• Published in: Breast cancer research : BCR Vol. 20; no. 1; p. 140
• Main Authors: Leech, Astrid O, Vellanki, Sri HariKrishna, Rutherford, Emily J, Keogh, Aoife, Jahns, Hanne, Hudson, Lance, O'Donovan, Norma, Sabri, Siham, Abdulkarim, Bassam, Sheehan, Katherine M, Kay, Elaine W, Young, Leonie S, Hill, Arnold D K, Smith, Yvonne E, Hopkins, Ann M
• Format: Journal Article
• Language: English
• Published: England BioMed Central 20-11-2018; BMC
• Subjects: AKT protein; Biomarkers; Breast cancer; Cancer therapies; Cell culture; Drug development; Drug resistance; Epidermal growth factor; ErbB-2 protein; HER2; HER2-targeted therapies; Immunotherapy; JAM-A; Kinases; Medical prognosis; Metastases; Metastasis; Monoclonal antibodies; Patients; Phenotypes; Phosphorylation; Protein expression; Proteins; Targeted cancer therapy; Therapeutic applications; Tight junction; Trastuzumab; Herceptin; HER2-targeted therapies; Tight junction; Breast cancer; JAM-A; Lapatinib; Drug resistance; HER2; Trastuzumab
• ISSN: 1465-542X; 1465-5411; 1465-542X
• DOI: 10.1186/s13058-018-1064-1

Junctional adhesion molecule-A (JAM-A) is an adhesion molecule whose overexpression on breast tumor tissue has been associated with aggressive cancer phenotypes, including human epidermal growth factor receptor-2 (HER2)-positive disease. Since JAM-A has been described to regulate HER2 expression in breast cancer cells, we hypothesized that JAM-dependent stabilization of HER2 could participate in resistance to HER2-targeted therapies.
Using breast cancer cell line models resistant to anti-HER2 drugs, we investigated JAM-A expression and the effect of JAM-A silencing on biochemical/functional parameters. We also tested whether altered JAM-A expression/processing underpinned differences between drug-sensitive and -resistant cells and acted as a biomarker of patients who developed resistance to HER2-targeted therapies.
Silencing JAM-A enhanced the anti-proliferative effects of anti-HER2 treatments in trastuzumab- and lapatinib-resistant breast cancer cells and further reduced HER2 protein expression and Akt phosphorylation in drug-treated cells. Increased epidermal growth factor receptor expression observed in drug-resistant models was normalized upon JAM-A silencing. JAM-A was highly expressed in all of a small cohort of HER2-positive patients whose disease recurred following anti-HER2 therapy. High JAM-A expression also correlated with metastatic disease at the time of diagnosis in another patient cohort resistant to trastuzumab therapy. Importantly, cleavage of JAM-A was increased in drug-resistant cell lines in conjunction with increased expression of ADAM-10 and -17 metalloproteases. Pharmacological inhibition or genetic silencing studies suggested a particular role for ADAM-10 in reducing JAM-A cleavage and partially re-sensitizing drug-resistant cells to the anti-proliferative effects of HER2-targeted drugs. Functionally, recombinant cleaved JAM-A enhanced breast cancer cell invasion in vitro and both invasion and proliferation in a semi-in vivo model. Finally, cleaved JAM-A was detectable in the serum of a small cohort of HER2-positive patients and correlated significantly with resistance to HER2-targeted therapy.
Collectively, our data suggest a novel model whereby increased expression and cleavage of JAM-A drive tumorigenic behavior and act as a biomarker and potential therapeutic target for resistance to HER2-targeted therapies.